<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33886568</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxazepam and cognitive reappraisal: A randomised experiment.</ArticleTitle>
        <Pagination>
          <StartPage>e0249065</StartPage>
          <MedlinePgn>e0249065</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0249065</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0249065</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Cognitive reappraisal is a strategy for emotional regulation, important in the context of anxiety disorders. It is not known whether anxiolytic effects of benzodiazepines affect cognitive reappraisal.</AbstractText>
          <AbstractText Label="AIMS">We aimed to investigate the effect of 25 mg oxazepam on cognitive reappraisal.</AbstractText>
          <AbstractText Label="METHODS">In a preliminary investigation, 33 healthy male volunteers were randomised to oxazepam or placebo, and then underwent an experiment where they were asked to use cognitive reappraisal to upregulate or downregulate their emotional response to images with negative or neutral emotional valence. We recorded unpleasantness ratings, skin conductance, superciliary corrugator muscle activity, and heart rate. Participants completed rating scales measuring empathy (Interpersonal Reactivity Index, IRI), anxiety (State-Trait Anxiety Inventory, STAI), alexithymia (Toronto Alexithymia Scale-20, TAS-20), and psychopathy (Psychopathy Personality Inventory-Revised, PPI-R).</AbstractText>
          <AbstractText Label="RESULTS">Upregulation to negative-valence images in the cognitive reappraisal task caused increased unpleasantness ratings, corrugator activity, and heart rate compared to downregulation. Upregulation to both negative- and neutral-valence images caused increased skin conductance responses. Oxazepam caused lower unpleasantness ratings to negative-valence stimuli, but did not interact with reappraisal instruction on any outcome. Self-rated trait empathy was associated with stronger responses to negative-valence stimuli, whereas self-rated psychopathic traits were associated with weaker responses to negative-valence stimuli.</AbstractText>
          <AbstractText Label="CONCLUSIONS">While 25 mg oxazepam caused lower unpleasantness ratings in response to negative-valence images, we did not observe an effect of 25 mg oxazepam on cognitive reappraisal.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nilsonne</LastName>
            <ForeName>Gustav</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-5273-0150</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychology, Stockholm University, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tamm</LastName>
            <ForeName>Sandra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychology, Stockholm University, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychology, University of Oxford, Oxford, England.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Golkar</LastName>
            <ForeName>Armita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Psychology, University of Amsterdam, Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olsson</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sörman</LastName>
            <ForeName>Karolina</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Howner</LastName>
            <ForeName>Katarina</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kristiansson</LastName>
            <ForeName>Marianne</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ingvar</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petrovic</LastName>
            <ForeName>Predrag</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6GOW6DWN2A</RegistryNumber>
          <NameOfSubstance UI="D010076">Oxazepam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080103" MajorTopicYN="N">Emotional Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010076" MajorTopicYN="N">Oxazepam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>17</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33886568</ArticleId>
        <ArticleId IdType="pmc">PMC8061924</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0249065</ArticleId>
        <ArticleId IdType="pii">PONE-D-20-19162</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Etkin A, Büchel C, Gross JJ. The neural bases of emotion regulation. Nature Reviews Neuroscience. 2015;16(11):693–700. 10.1038/nrn4044
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn4044</ArticleId>
            <ArticleId IdType="pubmed">26481098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petrovic P, Castellanos FX. Top-Down Dysregulation-From ADHD to Emotional Instability. Frontiers in Behavioral Neuroscience. 2016;10:70. 10.3389/fnbeh.2016.00070
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2016.00070</ArticleId>
            <ArticleId IdType="pmc">PMC4876334</ArticleId>
            <ArticleId IdType="pubmed">27242456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dåderman AM, Lidberg L. Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated, grievous violence in male juvenile offenders. The Journal of the American Academy of Psychiatry and the Law. 1999;27(1):83–99. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10212029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dåderman AM, Fredriksson B, Kristiansson M, Nilsson LH, Lidberg L. Violent behavior, impulsive decision-making, and anterograde amnesia while intoxicated with flunitrazepam and alcohol or other drugs: a case study in forensic psychiatric patients. Journal of the American Academy of Psychiatry and the Law Online. 2002;30(2):238–251. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12108561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dåderman AM, Fredriksson B, Nilsson LH, Kristiansson M, Lidberg L. The abuse of a sleeping pill that contains the active substance flunitrazepam (FZ)–for example, Rohypnol–and the effects of FZ intoxication, such as enhanced violence and disturbed memory. Journal of the American Academy of Psychiatry and the Law Online. 2004;32(4):467–468. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15704634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Braunstein LM, Gross JJ, Ochsner KN. Explicit and implicit emotion regulation: a multi-level framework. Social Cognitive and Affective Neuroscience. 2017;12(10):1545–1557. 10.1093/scan/nsx096
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/scan/nsx096</ArticleId>
            <ArticleId IdType="pmc">PMC5647798</ArticleId>
            <ArticleId IdType="pubmed">28981910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Golkar A, Lonsdorf TB, Olsson A, Lindstrom KM, Berrebi J, Fransson P, et al.. Distinct Contributions of the Dorsolateral Prefrontal and Orbitofrontal Cortex during Emotion Regulation. PLoS ONE. 2012;7(11):e48107. 10.1371/journal.pone.0048107
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048107</ArticleId>
            <ArticleId IdType="pmc">PMC3492343</ArticleId>
            <ArticleId IdType="pubmed">23144849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buhle JT, Silvers JA, Wager TD, Lopez R, Onyemekwu C, Kober H, et al.. Cognitive Reappraisal of Emotion: A Meta-Analysis of Human Neuroimaging Studies. Cerebral Cortex (New York, NY). 2014;24(11):2981–2990. 10.1093/cercor/bht154
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bht154</ArticleId>
            <ArticleId IdType="pmc">PMC4193464</ArticleId>
            <ArticleId IdType="pubmed">23765157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kanske P, Heissler J, Schönfelder S, Bongers A, Wessa M. How to regulate emotion? Neural networks for reappraisal and distraction. Cerebral Cortex (New York, NY: 1991). 2011;21(6):1379–1388. 10.1093/cercor/bhq216
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bhq216</ArticleId>
            <ArticleId IdType="pubmed">21041200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eippert F, Veit R, Weiskopf N, Erb M, Birbaumer N, Anders S. Regulation of emotional responses elicited by threat-related stimuli. Human Brain Mapping. 2007;28(5):409–423. 10.1002/hbm.20291
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hbm.20291</ArticleId>
            <ArticleId IdType="pmc">PMC6871321</ArticleId>
            <ArticleId IdType="pubmed">17133391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wager TD, Davidson ML, Hughes BL, Lindquist MA, Ochsner KN. Neural mechanisms of emotion regulation: Evidence for two independent prefrontal-subcortical pathways. Neuron. 2008;59(6):1037–1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2742320</ArticleId>
            <ArticleId IdType="pubmed">18817740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Archives of General Psychiatry. 2005;62(3):282–288. 10.1001/archpsyc.62.3.282
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.62.3.282</ArticleId>
            <ArticleId IdType="pubmed">15753241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schulze L, Domes G, Krüger A, Berger C, Fleischer M, Prehn K, et al.. Neuronal correlates of cognitive reappraisal in borderline patients with affective instability. Biological Psychiatry. 2011;69(6):564–573. 10.1016/j.biopsych.2010.10.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2010.10.025</ArticleId>
            <ArticleId IdType="pubmed">21195392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manber Ball T, Ramsawh HJ, Campbell-Sills L, Paulus MP, Stein MB. Prefrontal Dysfunction during Emotion Regulation in Generalized Anxiety and Panic Disorder. Psychological medicine. 2013;43(7):1475–1486. 10.1017/S0033291712002383
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0033291712002383</ArticleId>
            <ArticleId IdType="pmc">PMC4308620</ArticleId>
            <ArticleId IdType="pubmed">23111120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rabinak CA, MacNamara A, Kennedy AE, Angstadt M, Stein MB, Liberzon I, et al.. Focal and aberrant prefrontal engagement during emotion regulation in veterans with posttraumatic stress disorder. Depression and anxiety. 2014;31(10):851–861. 10.1002/da.22243
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/da.22243</ArticleId>
            <ArticleId IdType="pmc">PMC4141895</ArticleId>
            <ArticleId IdType="pubmed">24677490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bishop SJ. Neurocognitive mechanisms of anxiety: an integrative account. Trends in Cognitive Sciences. 2007;11(7):307–316. 10.1016/j.tics.2007.05.008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tics.2007.05.008</ArticleId>
            <ArticleId IdType="pubmed">17553730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Picó-Pérez M, Radua J, Steward T, Menchón JM, Soriano-Mas C. Emotion regulation in mood and anxiety disorders: A meta-analysis of fMRI cognitive reappraisal studies. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry. 2017;79(Pt B):96–104. 10.1016/j.pnpbp.2017.06.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2017.06.001</ArticleId>
            <ArticleId IdType="pubmed">28579400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bowins B. Cognitive regulatory control therapies. American Journal of Psychotherapy. 2013;67(3):215–236. 10.1176/appi.psychotherapy.2013.67.3.215
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.psychotherapy.2013.67.3.215</ArticleId>
            <ArticleId IdType="pubmed">24236353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nutt D. GABAA receptors: subtypes, regional distribution, and function. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2006;2(2):S7–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17557501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hörtnagl H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience. 2013;236:345–372. 10.1016/j.neuroscience.2013.01.008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2013.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC3605588</ArticleId>
            <ArticleId IdType="pubmed">23337532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: dissecting their pharmacological functions. Trends in Pharmacological Sciences. 2001;22(4):188–194. 10.1016/S0165-6147(00)01646-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-6147(00)01646-1</ArticleId>
            <ArticleId IdType="pubmed">11282419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, et al.. [18F]Flumazenil binding to central benzodiazepine receptor studies by PET: –Quantitative analysis and comparisons with [11C]flumazenil –. NeuroImage. 2009;45(3):891–902. 10.1016/j.neuroimage.2008.12.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroimage.2008.12.005</ArticleId>
            <ArticleId IdType="pubmed">19136064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pringle A, Warren M, Gottwald J, Cowen PJ, Harmer CJ. Cognitive mechanisms of diazepam administration: a healthy volunteer model of emotional processing. Psychopharmacology. 2016;233(12):2221–2228. 10.1007/s00213-016-4269-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-016-4269-y</ArticleId>
            <ArticleId IdType="pmc">PMC4873521</ArticleId>
            <ArticleId IdType="pubmed">27150079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Teixeira J, et al.. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. Psychopharmacology. 2020;237(1):1–9. 10.1007/s00213-019-05393-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-019-05393-y</ArticleId>
            <ArticleId IdType="pubmed">31740993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brown GG, Ostrowitzki S, Stein MB, von Kienlin M, Liu TT, Simmons A, et al.. Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder. Psychiatry Research: Neuroimaging. 2015;233(3):394–401. 10.1016/j.pscychresns.2015.06.016
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pscychresns.2015.06.016</ArticleId>
            <ArticleId IdType="pubmed">26211623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kreuder AK, Scheele D, Schultz J, Hennig J, Marsh N, Dellert T, et al.. Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear. Proceedings of the National Academy of Sciences. 2020;117(21):11781–11787. 10.1073/pnas.1920147117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1920147117</ArticleId>
            <ArticleId IdType="pmc">PMC7261088</ArticleId>
            <ArticleId IdType="pubmed">32385158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nilsonne G, Tamm S, Golkar A, Sörman K, Howner K, Kristiansson M, et al.. Effects of 25 mg oxazepam on emotional mimicry and empathy for pain: a randomized controlled experiment. Open Science. 2017;4(3):160607. 10.1098/rsos.160607
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rsos.160607</ArticleId>
            <ArticleId IdType="pmc">PMC5383810</ArticleId>
            <ArticleId IdType="pubmed">28405353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Horder J, Andersson M, Mendez MA, Singh N, Tangen M, Lundberg J, et al.. GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine. 2018;10(461). 10.1126/scitranslmed.aam8434
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aam8434</ArticleId>
            <ArticleId IdType="pubmed">30282698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang PJ, Bradley MM, Cuthbert BN. International affective picture system (IAPS): Affective ratings of pictures and instruction manual. Technical report A-8. 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>
Fridlund AJ, Cacioppo JT. Guidelines for Human Electromyographic Research. Psychophysiology. 1986;23(5):567–589. 10.1111/j.1469-8986.1986.tb00676.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-8986.1986.tb00676.x</ArticleId>
            <ArticleId IdType="pubmed">3809364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davis M. A multidimensional approach to individual differences in empathy. JSAS Catalog of Selected Documents in Psychology. 1980;10(85).</Citation>
        </Reference>
        <Reference>
          <Citation>
Davis MH. Measuring individual differences in empathy: Evidence for a multidimensional approach. Journal of Personality and Social Psychology. 1983;44(1):113–126. 10.1037/0022-3514.44.1.113</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/0022-3514.44.1.113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cliffordson C. Parents’ Judgments and Students’ Self-Judgments of Empathy. European Journal of Psychological Assessment. 2001;17(1):36–47. 10.1027//1015-5759.17.1.36</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1027//1015-5759.17.1.36</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spielberger C, Gorsuch R, Lushene P, Vagg P. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Inc., Palo Alto, CA; 1983.</Citation>
        </Reference>
        <Reference>
          <Citation>Nilsonne G. Data-and-analysis-code-Oxazepam-and-emotion: Release for publication. Zenodo; 2016. Available from: https://zenodo.org/record/60385#.WWLIbYgrJnI.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia scale—I. Item selection and cross-validation of the factor structure. Journal of Psychosomatic Research. 1994;38(1):23–32. 10.1016/0022-3999(94)90005-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-3999(94)90005-1</ArticleId>
            <ArticleId IdType="pubmed">8126686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simonsson-Sarnecki M, Lundh LG, Törestad B, Bagby RM, Taylor G, Parker J. A Swedish Translation of the 20-item Toronto Alexithymia Scale: Cross-validation of the Factor Structure. Scandinavian Journal of Psychology. 2000;41(1):25–30. 10.1111/1467-9450.00167
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1467-9450.00167</ArticleId>
            <ArticleId IdType="pubmed">10731840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lilienfeld SO, Andrews BP. Development and Preliminary Validation of a Self-Report Measure of Psychopathic Personality Traits in Noncriminal Population. Journal of Personality Assessment. 1996;66(3):488–524. 10.1207/s15327752jpa6603_3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1207/s15327752jpa6603_3</ArticleId>
            <ArticleId IdType="pubmed">8667144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Benning SD, Patrick CJ, Hicks BM, Blonigen DM, Krueger RF. Factor structure of the psychopathic personality inventory: validity and implications for clinical assessment. Psychological Assessment. 2003;15(3):340–350. 10.1037/1040-3590.15.3.340
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/1040-3590.15.3.340</ArticleId>
            <ArticleId IdType="pubmed">14593834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sörman K, Nilsonne G, Howner K, Tamm S, Caman S, Wang HX, et al.. Reliability and Construct Validity of the Psychopathic Personality Inventory-Revised in a Swedish Non-Criminal Sample—A Multimethod Approach including Psychophysiological Correlates of Empathy for Pain. PLOS ONE. 2016;11(6):e0156570. 10.1371/journal.pone.0156570
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0156570</ArticleId>
            <ArticleId IdType="pmc">PMC4907435</ArticleId>
            <ArticleId IdType="pubmed">27300292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. Available from: http://www.R-project.org/.</Citation>
        </Reference>
        <Reference>
          <Citation>Lang DT. RCurl: General network (HTTP/FTP/…) client interface for R; 2015. Available from: http://CRAN.R-project.org/package=RCurl.</Citation>
        </Reference>
        <Reference>
          <Citation>Ryan JA. quantmod: Quantitative Financial Modelling Framework; 2015. Available from: http://CRAN.R-project.org/package=quantmod.</Citation>
        </Reference>
        <Reference>
          <Citation>Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models; 2015. Available from: http://CRAN.R-project.org/package=nlme.</Citation>
        </Reference>
        <Reference>
          <Citation>
Fox J. Effect displays in R for generalised linear models. Journal of Statistical Software. 2003;8(15):1–27. 10.18637/jss.v008.i15</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18637/jss.v008.i15</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuwirth E. RColorBrewer: ColorBrewer Palettes; 2014. Available from: http://CRAN.R-project.org/package=RColorBrewer.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ray RD, McRae K, Ochsner KN, Gross JJ. Cognitive Reappraisal of Negative Affect: Converging Evidence From EMG and Self-Report. Emotion (Washington, DC). 2010;10(4):587–592. 10.1037/a0019015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/a0019015</ArticleId>
            <ArticleId IdType="pmc">PMC4106258</ArticleId>
            <ArticleId IdType="pubmed">20677875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M. Placebo in emotional processing–induced expectations of anxiety relief activate a generalized modulatory network. Neuron. 2005;46(6):957–969. 10.1016/j.neuron.2005.05.023
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2005.05.023</ArticleId>
            <ArticleId IdType="pubmed">15953423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Olofsson JK, Gospic K, Petrovic P, Ingvar M, Wiens S. Effects of oxazepam on affective perception, recognition, and event-related potentials. Psychopharmacology. 2011;215(2):301–309. 10.1007/s00213-010-2141-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-010-2141-z</ArticleId>
            <ArticleId IdType="pubmed">21197615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baas JMP, Grillon C, Böcker KBE, Brack AA, Morgan CA, Kenemans JL, et al.. Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology. 2002;161(3):233–247. 10.1007/s00213-002-1011-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-002-1011-8</ArticleId>
            <ArticleId IdType="pubmed">12021826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Acheson DT, Stein MB, Paulus MP, Ravindran L, Simmons AN, Lohr JB, et al.. Effects of anxiolytic treatment on potentiated startle during aversive image anticipation. Human Psychopharmacology. 2012;27(4):419–427. 10.1002/hup.2243
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hup.2243</ArticleId>
            <ArticleId IdType="pubmed">22782542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schiller D, Delgado MR. Overlapping neural systems mediating extinction, reversal and regulation of fear. Trends in Cognitive Sciences. 2010;14(6):268–276. 10.1016/j.tics.2010.04.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tics.2010.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC3848321</ArticleId>
            <ArticleId IdType="pubmed">20493762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Milad MR, Quirk GJ. Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress. Annual review of psychology. 2012;63:129–151. 10.1146/annurev.psych.121208.131631
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.psych.121208.131631</ArticleId>
            <ArticleId IdType="pmc">PMC4942586</ArticleId>
            <ArticleId IdType="pubmed">22129456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Levy I, Schiller D. Neural Computations of Threat. Trends in Cognitive Sciences. 2021;25(2):151–171. 10.1016/j.tics.2020.11.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tics.2020.11.007</ArticleId>
            <ArticleId IdType="pmc">PMC8084636</ArticleId>
            <ArticleId IdType="pubmed">33384214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Walker S, O’Connor DB, Schaefer A. Brain potentials to emotional pictures are modulated by alexithymia during emotion regulation. Cognitive, Affective, &amp; Behavioral Neuroscience. 2011;11(4):463–475. 10.3758/s13415-011-0042-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3758/s13415-011-0042-1</ArticleId>
            <ArticleId IdType="pubmed">21614450</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
